Trends in the pharmacologic management of insomnia

Journal of Clinical Psychiatry

Volumn 67, Issue SUPPL. 13, 2006, Pages 5-8

  Doghramji, Paul P ^a  

^a Collegeville Family Practice ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; ESTAZOLAM; ESZOPICLONE; FLURAZEPAM; GABOXADOL; HYPNOTIC AGENT; INDIPLON; NEUROLEPTIC AGENT; NON PRESCRIPTION DRUG; QUAZEPAM; RAMELTEON; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; ZALEPLON; ZOLPIDEM;

CLINICAL TRIAL; DIABETES MELLITUS; DOSE RESPONSE; DRUG APPROVAL; DRUG RELEASE; FALLING; FOOD AND DRUG ADMINISTRATION; HALF LIFE TIME; HUMAN; INSOMNIA; ORTHOSTATIC HYPOTENSION; PRIAPISM; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 33845368989     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Walsh JK, Schweitzer PK. Ten-year trends in the pharmacological treatment of insomnia. Sleep 1999;22:371-375
2. National Institutes of Health. NIH State-of-the-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. June 13-15, 2005. Available at: http://consensus.nih.gov/2005/2005InsomniaSOS026PDF. pdf. Accessed April 20, 2006
3. Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM III-R primary insomnia. Hum Psychopharmacol 1998;13:191-198
4. Sonata [prescribing information]. Philadelphia, Pa: Wyeth Pharmaceuticals; 2006. Available at: http://www.kingpharm.com/uploads/ pdf_inserts/Sonata_Web_PI.pdf. Accessed June 13, 2006
5. Ambien [prescribing information]. New York, NY: Sanofi-Synthelabo; 2004. Available at: http://products.sanofi-aventis.us/ambien/ambien.html. Accessed June 13, 2006
6. Ambien CR [prescribing information]. New York, NY: Sanofi-Synthelabo; 2005. Available at: http://products.sanofi-aventis.us/ambien_cr/ambienCR.html. Accessed June 13, 2006
7. Lunesta [prescribing information]. Marlborough, Mass: Sepracor, Inc: 2005. Available at: http://www.lunesta.com/PostedApprovedLabelingText.pdf. Accessed June 13, 2006
8. Rozerem [prescribing information]. Lincolnshire, Ill: Takeda Pharmaceuticals America; 2005. Available at: http://www.rozerem.com/images/pi. pdf. Accessed June 13, 2006
9. Ancoli-Israel S, Richardson GS, Mangano RM, et al. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med 2005;6:107-113
10. Perlis MP, McCall WV, Krystal AD, et al. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 2004;65:1128-1137
11. Erman M. Krystal A, Zammit G, et al. Zolpidem extended-release 12.5-mg, taken for 24 weeks "as needed" up to 7 nights/week, improves subjective measures of therapeutic global impression, sleep onset, and sleep maintenance in patients with chronic insomnia. In: Abstracts from the XXV CINP Congress; July 9-13, 2006: Chicago, Ill. Abstract P03.106:S256
12. Halas CJ. Eszopiclone. Am J Health Syst Pharm 2006;63:41-48
13. Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 2006;7:17-24
14. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26:793-799
15. Roth T, Walsh JK, Krystal A, et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005;6:487-495
16. Roth T, Seiden D, Sainati S, et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006;7:312-318
17. Lankford DL, Klee B, Kean Y, et al. Efficacy and tolerability of indiplon in primary insomnia: results of a double-blind, placebo-controlled, four-week trial. In: New Research Abstracts of the 159th Annual Meeting of the American Psychiatric Association; May 20-25, 2006; Toronto, Ontario, Canada. Abstract NR537:223
18. Lundahl J, Staner L, Staner C, et al. Gaboxadol improves sleep maintenance and, in contrast to zolpidem, enhances slow wave sleep in adult patients with primary insomnia. In: New Research Abstracts of the 159th Annual Meeting of the American Psychiatric Association; May 20-25, 2006; Toronto, Ontario, Canada. Abstract NR823:341
19. Walsh JK, Deacon S, Dijk D, et al. Gaboxadol improves sleep onset and maintenance and enhances low frequency components of NREM sleep EEG in a model of transient insomnia. In: New Research Abstracts of the 159th Annual Meeting of the American Psychiatric Association; May 20-25, 2006; Toronto, Ontario, Canada. Abstract NR869:361